Coriell, U.S. Air Force Authors Collaborate on PublicationJanuary 2017
The Coriell Personalized Medicine Collaborative (CPMC) was established in 2007 as a prospective study to evaluate the clinical utility of personal genomic information for common complex disease and pharmacogenomics among both disease-specific and healthy cohorts.
In 2010 the Air Force Medical Service (AFMS) Patient-Centered Precision Care (PC2-Z) Program was established as an Air Force Surgeon General Directive and launched by the AFMS Innovations program to gather clinical knowledge and provide recommendations for translating genome-informed medicine into precision healthcare for all Air Force healthcare beneficiaries. Recognizing its established infrastructure, the CPMC was chosen in 2011 as a key partner in the PC2-Z Program, enabling Coriell to enroll service men and women - and their spouses - into a customized, multi-center United States Air Force clinical utility study (CUS).
Now in its sixth year, the Coriell-Air Force research partnership has produced a wide variety of insights, including the critical features of optimal study design for military-sponsored genomic research. In a paper just published in the Nature Partner Journal, Genomic Medicine, Coriell and Air Force authors discuss the challenges faced and critical success factors for military-civilian collaborations centered on genomics.
Coriell President and CEO and CPMC principal investigator, Dr. Michael Christman, adds, "The CPMC-Air Force project has been a rewarding endeavor for both parties, owing its successes to the Air Force participants whose involvement drive this research forward."
The paper titled, "Precision Military Medicine: Conducting a multi-site clinical utility study of genomic and lifestyle risk factors in the United States Air Force," can be accessed here.